Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Shulman

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Drug Targets. Infectious Disorders|February 3, 2004
A review of HIV-1 resistance to the nucleoside and nucleotide inhibitorsNancy Shulman, Mark Winters
The AIDS Reader|February 3, 2005
NNRTI hypersusceptibilityJamael Delgado, Nancy Shulman
Retrovirology|January 29, 2008
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patientsAmit Kapoor, Beth Shapiro, Robert W Shafer, et al.
Clinical Drug Investigation|April 6, 2017
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III StudiesChih-Wei Lin, Rajeev Menon, Wei Liu, et al.
Plos One|August 21, 2014
Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencingSeverine Margeridon-Thermet, Sophie Le Pogam, Lewyn Li, et al.
European Journal of Clinical Pharmacology|July 23, 2013
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktailPeter N Morcos, Linda Chang, Rohit Kulkarni, et al.
Antimicrobial Agents and Chemotherapy|March 19, 2002
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapyRami Kantor, W Jeffrey Fessel, Andrew R Zolopa, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremiaNancy Shulman, Andrew Zolopa, Diane Havlir, et al.
The Journal of Infectious Diseases|December 12, 2017
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin DosageAndrew H Talal, Emily O Dumas, Barbara Bauer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Drug Targets. Infectious Disorders|February 3, 2004
A review of HIV-1 resistance to the nucleoside and nucleotide inhibitorsNancy Shulman, Mark Winters
The AIDS Reader|February 3, 2005
NNRTI hypersusceptibilityJamael Delgado, Nancy Shulman
Retrovirology|January 29, 2008
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patientsAmit Kapoor, Beth Shapiro, Robert W Shafer, et al.
Clinical Drug Investigation|April 6, 2017
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III StudiesChih-Wei Lin, Rajeev Menon, Wei Liu, et al.
Plos One|August 21, 2014
Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencingSeverine Margeridon-Thermet, Sophie Le Pogam, Lewyn Li, et al.
European Journal of Clinical Pharmacology|July 23, 2013
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktailPeter N Morcos, Linda Chang, Rohit Kulkarni, et al.
Antimicrobial Agents and Chemotherapy|March 19, 2002
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapyRami Kantor, W Jeffrey Fessel, Andrew R Zolopa, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremiaNancy Shulman, Andrew Zolopa, Diane Havlir, et al.
The Journal of Infectious Diseases|December 12, 2017
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin DosageAndrew H Talal, Emily O Dumas, Barbara Bauer, et al.
Pageof 1